# Metro-Minnesota Community Oncology Research Consortium (MMCORC)

> **NIH NIH UG1** · HEALTHPARTNERS INSTITUTE · 2022 · $4,033,630

## Abstract

Project Summary
The Metro-Minnesota Community Oncology Research Consortium (MMCORC), formerly known as the Metro-
Minnesota Community Clinical Oncology Program (MMCCOP), has a long history of success, as demonstrated
by the ongoing commitment of is original members and the consortium's growth from 1979 to 2018. Today,
MMCORC is an established community program that began through its National Cancer Institute (NCI)-funded
Community Hospital Cancer Program Award. This program improved cancer care delivery in the community
and was the cornerstone for the Community Clinical Oncology Program (CCOP) initiative. It received the initial
NCI CCOP grant in 1983 and has been awarded subsequent CCOP grants in 3- to 5-year increments until the
5-year NCI Community Oncology Research Program (NCORP) grant in 2014. In 2010, hospitals, clinics, and
oncologists in the MN Community Group Outreach Program joined MMCCOP, resulting in a metro-wide
community cancer research program in Minneapolis-St. Paul. In 2014, MMCCOP received funding under the
new NCORP grant program. In 2016, MMCCOP was renamed MMCORC to represent the disbanding of the
NCI CCOP grant program and show the broad scope of oncology research services available to the
community, consistent with a consortium model. MMCORC represents 25 hospital and clinics with a common
approach and established mechanisms for identifying, enrolling, and following participants on NCI- sponsored
treatment, cancer prevention and control, symptom management, and care delivery research protocols. The
state health market remains extremely competitive and is constantly changing due to mergers and healthcare
reform initiatives. Despite this environment, MMCORC hospitals and staff continue to collaborate and support
the added time and expense of offering clinical research trials to patients in the communities we serve.
The consortium incorporates a substantial segment of the oncology community and has provided a basis for
communication, partnership, and collaboration among practicing oncologists, their hospital administrators, and
other health professionals for 35 years. Combined, the consortium members see, on average, more than
17,170 new analytic cancer patients per year. In the consortium, 165 MD investigators represent medical
oncology, hematology, and radiation and surgical oncology, including thoracic surgery, gynecologic oncology,
radiology, neuro-oncology, obstetrics and gynecology, palliative care, and primary care, with 57 mid-level
clinicians (nurse practitioners and physician assistants) considered associate investigators.
MMCORC intends to continue to offer the community the most recent advances in cancer prevention,
treatment, symptom management, and care delivery through continued affiliations with NCORP research
bases such as Alliance, ECOG-ACRIN, NRG Oncology, SWOG via CTSU, URCC, and CCCWFU. By
implementing proactive strategies to improve access and encourage participation from underrepresented and
underserved...

## Key facts

- **NIH application ID:** 10460122
- **Project number:** 5UG1CA189863-10
- **Recipient organization:** HEALTHPARTNERS INSTITUTE
- **Principal Investigator:** Daniel M Anderson
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $4,033,630
- **Award type:** 5
- **Project period:** 2014-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10460122

## Citation

> US National Institutes of Health, RePORTER application 10460122, Metro-Minnesota Community Oncology Research Consortium (MMCORC) (5UG1CA189863-10). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10460122. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*